Snoretox wins the 2025 Innovation Award at the Animal Health Summit in Kansas city
Posted: 6 October 2025 Snoretox has won the Emerging Company Innovation Award at the global Veterinarian new products conference KCAnimalHealth Summit in the USA. This convention is the leading deal-making convention for veterinary pharmaceutical companies in the USA,…
Chimeric Therapeutics reports tumour reduction in CHM CDH17 Phase 1/2 trial
Posted: 30 September 2025 Chimeric Therapeutics announced further evidence of disease control and tumour shrinkage in its CHM CDH17 Phase 1/2 clinical trial, following confirmation by the Safety Monitoring Committee that Dose Level 2 is safe for additional…
Monash University partners with South Korea’s K-Bio Lab Hub to establish first Australian biotech launchpad
Posted: 29 September 2025 Monash University announced a new Memorandum of Understanding (MoU) with South Korea’s government-backed biotech incubator, K-Bio Lab Hub, to create the organisation’s first Australian launchpad in Melbourne. The collaboration, centred within the Monash Technology…
RMIT’s 3D-printed diamond titanium device to power next generation implants
Posted: 29 September 2025 RMIT University researchers announced the development of an experimental 3D-printed diamond–titanium device that generated electricity from flowing liquid and wirelessly received power through tissue, allowing remote monitoring of changes in flow. The innovation was…
University of Melbourne awarded $9 million for three new NHMRC Centres of Research Excellence
Posted: 29 September 2025 The University of Melbourne was awarded $9 million in funding for three new Centres of Research Excellence (CREs), designed to address pressing health and sustainability challenges. The funding, announced by the Minister for Health…
Cureator allocates $15.7 million to advance dementia and cognitive decline innovations
Posted: 25 September 2025 The Brandon Capital managed Cureator, in partnership with ANDHealth and Dementia Australia, confirmed the allocation of $15,765,871 to seven companies developing medical technologies for dementia and cognitive decline. The initiative was supported by the…
Starpharma secures $855 million cancer therapy partnership with Genentech
Posted: 25 September 2025 Starpharma announced a landmark global licensing agreement with Genentech, a Roche Group company, to advance cancer treatments using its proprietary DEP® drug delivery platform. The collaboration provided Starpharma with an upfront payment of USD…
CBE Pure Solutions receives TGA licence to manufacture sterile clinical trial liquids for Phase 2 and 3 clinical trials
Posted: 24 September 2025 CBE Pure Solutions has received expanded licence from the Therapeutic Goods Administration (TGA). Their TGA licence now includes sterile fill-and-finish and labelling for injectables and infusions for all clinical trial phases (1-3). In addition,…
BioMelbourne Network’s Modernising clinical trials BioSymposium explores execution, access and impact for new directions in the clinical trials sector
Posted: 17 September 2025 With the theatrette at Melbourne Museum filled with around 150 curious and eager-to-learn attendees generating lively discussions, the second BioMelbourne Network BioSymposium of 2025, ‘Modernising clinical trials: Execution, access and impact’, brought the sector…
Stephens Lawyers & Consultants release guidance on protecting confidential information and trade secrets in Australia
Posted: 17 September 2025 Stephens Lawyers & Consultants recently released an article examining how confidential information and trade secrets are protected under Australian law . The publication emphasised that these assets can easily lose value if improperly disclosed,…
WEHI team awarded 2025 Eureka Prize for Parkinson’s disease research
Posted: 17 September 2025 A research team from WEHI’s Parkinson’s Disease Research Centre was awarded the 2025 Eureka Prize for Scientific Research for discoveries that revealed how a key protein linked to early-onset Parkinson’s disease functions. The Eureka…
Oncology One, Pfizer, WEHI, Cancer Therapeutics CRC and partners advance Australian-discovered KAT6 inhibitor into Phase 3 breast cancer trial
Posted: 17 September 2025 Oncology One Pty Ltd reported that Pfizer Inc’s clinical candidate PF-07248144, a first-in-class KAT6 inhibitor originating from Australian research, had entered a Phase 3 clinical trial for hormone receptor positive, HER2-negative breast cancer. PF-07248144…
